Novartis AG beats Q2 2025 expectations, but patent expiries and policy risks loom. Click for my updated look at NVS earnings ...

Today's US data is generally on the firmer side in terms of activity and jobs, while import prices are a touch softer than ...

Increased assortment and category expansion. Stitch Fix continues to see stronger growth in its Men's category than Women's, ...

Trump's tariffs risk inflation and recession, straining markets and growth. Read about how I recommend investing while ...

Discover why Takeda Pharmaceutical Company Limited remains a solid Buy. Click to explore TAK and its drug pipeline, growth ...

CRWV has had an exciting H1'25 performance, thanks to the recent IPO, the growing demand for its neocloud offerings, and the ...

Chagee (CHA) re-enters Vietnam's market after controversy, addressing sovereignty concerns with a revised strategy.

BSV offers diversified exposure to short-term investment-grade bonds, with low duration risk and a current yield to maturity ...

Udemy faces growth slowdown, declining consumer interest, and enterprise challenges. Learn why profitability efforts may not ...

I've sold 84% of my EPR Properties position after strong gains, reallocating to new opportunities for better risk/reward.

Tarsus Pharmaceuticals' stock faces challenges despite XDEMVY's success. Analysts remain bullish with price targets of ...

A merger would be likely to face major regulatory scrutiny. CSX Corporation ( NASDAQ: CSX) has a market cap of over $62 ...